Orforglipron Pill Keeps Weight Off After Wegovy, Mounjaro
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Orforglipron trial tracked 376 US patients who had been on tirzepatide (Mounjaro) or semaglutide (Wegovy) injections for 72 weeks, then randomized them to the daily pill or a placebo for a year, per results published in Nature Medicine.
- Weight retention: tirzepatide users who switched to the pill kept almost 75% of weight off versus 49% for those on placebo, while semaglutide users kept almost 80% versus 38% on placebo.
- Cardiometabolic markers — blood pressure, cholesterol, and blood sugar improvements from the injections persisted after patients moved to orforglipron, the authors reported.
- Eli Lilly, which manufactures Mounjaro and funded the trial, presented the data at the European Congress on Obesity 2026 in Istanbul.
- Cost angle: Dr. Simon Cork of Anglia Ruskin University said injectable GLP-1s are expensive and limit long-term use for private buyers and the NHS, while oral medications are "significantly cheaper to manufacture" though they typically produce less weight loss.
- Chronic-disease framing: Dr. Louis Aronne of Weill Cornell Medicine argued obesity should be treated like other chronic diseases, noting the average patient in his clinic has a BMI of 38, takes seven medications, and has sleep apnoea.
- Rebound prevention: previous studies showed patients regain two-thirds of lost weight within a year of stopping jabs — a gap the new trial suggests orforglipron can close.
Why it matters: For the roughly 30% of UK adults living with obesity — many of whom take Wegovy or Mounjaro alongside about seven other medications — an oral maintenance option could ease long-term cost and treatment burden on the NHS while preserving the blood-pressure, cholesterol, and blood-sugar gains that normally disappear when jabs stop.
